- Home
- AVX vs CGTX Comparison
AVX vs CGTX Comparison
Compare AVX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVX | CGTX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 132.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AVX | CGTX |
|---|---|---|
| Price | $1.74 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 132.1K | ★ 957.6K |
| Earning Date | 03-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,319,011.00 | N/A |
| Revenue This Year | $530,767.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8001.54 | N/A |
| 52 Week Low | $1.12 | $0.22 |
| 52 Week High | $25.38 | $3.83 |
Technical Indicators
Market Signals| Indicator | AVX | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.98 |
| Support Level | N/A | $1.33 |
| Resistance Level | N/A | $1.62 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 33.72 |
Price Performance
Historical ComparisonAbout AVX Avax One Technology Ltd.
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.